Rate of Severe COPD Exacerbations with Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Dual Therapies: A Post-Hoc Analysis of the ETHOS Trial Excluding Data from China
单位：[1]Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA[2]LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany[3]Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY, USA[4]Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester, UK[5]AstraZeneca, Durham, NC, USA[6]AstraZeneca, Wilmington, DE, USA[7]AstraZeneca, Cambridge, UK[8]AstraZeneca, Gothenburg, Sweden
第一作者单位：[1]Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA
推荐引用方式(GB/T 7714)：
Ferguson G. T.,Rabe K. F.,Martinez F. J.,et al.Rate of Severe COPD Exacerbations with Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Dual Therapies: A Post-Hoc Analysis of the ETHOS Trial Excluding Data from China[J].AMERICAN JOURNAL of RESPIRATORY and CRITICAL CARE MEDICINE.2020,201:
APA：
Ferguson, G. T.,Rabe, K. F.,Martinez, F. J.,Wang, C.,Trivedi, R....&Darken, P..(2020).Rate of Severe COPD Exacerbations with Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Dual Therapies: A Post-Hoc Analysis of the ETHOS Trial Excluding Data from China.AMERICAN JOURNAL of RESPIRATORY and CRITICAL CARE MEDICINE,201,
MLA：
Ferguson, G. T.,et al."Rate of Severe COPD Exacerbations with Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Dual Therapies: A Post-Hoc Analysis of the ETHOS Trial Excluding Data from China".AMERICAN JOURNAL of RESPIRATORY and CRITICAL CARE MEDICINE 201.(2020)
医学